Previous 10 | Next 10 |
Hologic press release (NASDAQ:HOLX): Q1 Non-GAAP EPS of $2.17 beats by $0.96. Revenue of $1.47B (-8.7% Y/Y) beats by $260M. Shares +5%. Q2 2022 Guidance: Revenue to range between $1.25-$1.3B vs. consensus of $1.06B; GAAP EPS of $1.22-$1.32; Non-GAAP EPS of $1.50-$1.60 vs. consensus of $0.90. ...
– Revenue of $1.471 Billion, GAAP Diluted EPS of $1.95, and Non-GAAP Diluted EPS of $2.17 All Significantly Exceed Expectations – – Broad-Based Organic Revenue Growth of 9% Excluding COVID; Each Division Above 8% Global Growth Excluding COVID – ȁ...
Hologic (NASDAQ:HOLX) is scheduled to announce FQ1 earnings results on Tuesday, February 1st, after market close. The consensus EPS Estimate is $1.21 (-57.7% Y/Y) and the consensus Revenue Estimate is $1.21B (-24.8% Y/Y). Over the last 2 years, HOLX has beaten EPS estimates 75% of the time an...
--Leader in women’s health shines spotlight on preventive screenings in commercial created by women, for women premiering during one of America's biggest events-- Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving wom...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Hologic, Inc. (Nasdaq: HOLX) announced today the online publication of “A Global Force for Good,” a report detailing the Company’s environmental, social and governance (ESG) achievements in 2021. This press release features multimedia. View the full release ...
You don't need a fortune to invest in the stock market and build wealth. A $5,000 investment that grows 10% for 20 years would end up being worth more than $33,000. While you won't be able to retire off of that, the more quality $5,000 investments you can afford to make, the more likely you...
– Revenue of $1,471.1 Million Significantly Exceeds Guidance – – Organic Revenue Grows 9% Excluding COVID-19 Benefits – – More than 8% Global Organic Growth in All Businesses: Breast, Surgical, Skeletal and Diagnostics ex-COVID – ...
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2022 on Wednesday, February 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. East...
Hologic, Inc. (NASDAQ: HOLX) announces the addition of the Aptima® SARS-CoV-2 assay to its Global Access Initiative (GAI), a program designed to expand access to critical diagnostic testing in resource-limited countries. As a global leader in diagnostics, Hologic launched t...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...